While certain cell types, including human glioblastoma (GBM), showed resistance to TRAIL, we found that the expression of TRAIL‐binding surface proteins was predictive of each cell type's resistance to TRAIL therapy. The gene discussed is TNFSF10; the disease is glioblastoma.